Karyopharm to Participate at Upcoming Investor Conferences
Karyopharm (Nasdaq: KPTI) announced that senior management will participate in two May 2026 investor conferences via fireside chats: the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Karyopharm (Nasdaq: KPTI) announced that senior management will participate in two May 2026 investor conferences via fireside chats: the H.C. Wainwright 4th Annual BioConnect Investor Conference and the RBC 2026 Global Healthcare Conference, both on May 19, 2026.
Live webcasts and replays will be available in the Events & Presentations section of Karyopharm's investor relations website.
Details
News Market Reaction – KPTI
On May 12, the day this news came out, KPTI closed 1.19% above the previous close.
Data tracked by StockTitan Argus for the May 12 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
H.C. Wainwright 4th Annual BioConnect Investor Conference
Format: Fireside chat
Date: Tuesday, May 19, 2026
Time: 9:00 a.m. ET
RBC 2026 Global Healthcare Conference
Format: Fireside chat
Date: Tuesday, May 19, 2026
Time: 3:35 p.m. ET
A live webcast of the fireside chats can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay following the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-upcoming-investor-conferences-302768660.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
